Conference
Ixekizumab Improves Patient-Reported Outcomes through 52 Weeks in Patients with Active Psoriatic Arthritis and Previous Inadequate Response to Tumor Necrosis Factor-Inhibitors
Authors
Kavanaugh A; Marzo-Ortega H; Vender R; Birt J; Adams D; Benichou O; Lin C-Y; Nash P
Volume
69
Publisher
WILEY
Publication Date
10 2017
Name of conference
81st Annual Meeting of the American-College-of-Rheumatology (ACR) / Association-of-Rheumatology-Health-Professionals (ARHP)
Conference place
CA, San Diego
Conference start date
November 3, 2017
Conference end date
November 8, 2017
Conference proceedings
ARTHRITIS & RHEUMATOLOGY
ISSN
2326-5191